In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glenmark Pharmaceuticals Ltd.

www.glenmarkpharma.com

Latest From Glenmark Pharmaceuticals Ltd.

Newbie Remogliflozin Gives Competition A Run For Their Money

Remogliflozin prescriptions gallop in India and Glenmark expects the ‘affordable’ therapy to take share from other SGLT2 inhibitors.

Commercial Strategy

Lupin-Aptar Launch India’s First Smart Device For MDIs At $22 Apiece

As the Indian pharma industry catches up with digitization, Lupin partners with Aptar to launch a smart device for MDIs. While there is a need for the product, whether it will find favor in a price-sensitive market remains to be seen. 

Commercial India

New Indication For Lenvima In India Spawns Opportunities For Many?

Eisai’s lenvatinib is endorsed by an expert panel in India in combination with everolimus, for which multiple generic brands are available in addition to Novartis’ Afinitor. The Swiss multinational isn’t allying with Eisai in India at least for now.

Policy & Regulation India

Monroe Site ‘Critical’ For Glenmark In US

Glenmark expects its first US manufacturing site to go commercial next year, accelerating growth in that market, while it sets right certain compliance blips back home. The Indian firm is also on course to divest certain non-core assets but notes that bringing in a minority partner for its API unit is not a priority.

Strategy Sales & Earnings
See All

Company Information

UsernamePublicRestriction

Register